Under det kliniske sikkerhedsstudie af virkningen, er der set bivirkninger, der kan være relaterede til Oxyglobin og/ eller den tilgrundliggende sygdom, der forårsager blodmangelen.
During the clinical safety and efficacy study, adverse events were seen which may have been related to Oxyglobin and/ or the underlying disease causing anaemia.